NeurogesX, a biopharmaceutical company focused on developing on commercializing novel pain management therapies, filed for an IPO on Wednesday. Morgan Stanley is the lead manager on the deal. Terms and timing are yet to be announced.
NeurogesX, a biopharmaceutical company focused on developing on commercializing novel pain management therapies, filed for an IPO on Wednesday. Morgan Stanley is the lead manager on the deal. Terms and timing are yet to be announced.